Impact of seed amplification assay and surface-enhanced Raman spectroscopy combined approach on the clinical diagnosis of Alzheimer’s disease

Background The current diagnosis of Alzheimer’s disease (AD) is based on a series of analyses which involve clinical, instrumental and laboratory findings. However, signs, symptoms and biomarker alterations observed in AD might overlap with other dementias, resulting in misdiagnosis. Methods Here we...

Full description

Saved in:
Bibliographic Details
Published inTranslational neurodegeneration Vol. 12; no. 1; pp. 35 - 12
Main Authors D’Andrea, Cristiano, Cazzaniga, Federico Angelo, Bistaffa, Edoardo, Barucci, Andrea, de Angelis, Marella, Banchelli, Martina, Farnesi, Edoardo, Polykretis, Panagis, Marzi, Chiara, Indaco, Antonio, Tiraboschi, Pietro, Giaccone, Giorgio, Matteini, Paolo, Moda, Fabio
Format Journal Article
LanguageEnglish
Published London BioMed Central 12.07.2023
BMC
Subjects
Online AccessGet full text
ISSN2047-9158
2047-9158
DOI10.1186/s40035-023-00367-9

Cover

More Information
Summary:Background The current diagnosis of Alzheimer’s disease (AD) is based on a series of analyses which involve clinical, instrumental and laboratory findings. However, signs, symptoms and biomarker alterations observed in AD might overlap with other dementias, resulting in misdiagnosis. Methods Here we describe a new diagnostic approach for AD which takes advantage of the boosted sensitivity in biomolecular detection, as allowed by seed amplification assay (SAA), combined with the unique specificity in biomolecular recognition, as provided by surface-enhanced Raman spectroscopy (SERS). Results The SAA-SERS approach supported by machine learning data analysis allowed efficient identification of pathological Aβ oligomers in the cerebrospinal fluid of patients with a clinical diagnosis of AD or mild cognitive impairment due to AD. Conclusions Such analytical approach can be used to recognize disease features, thus allowing early stratification and selection of patients, which is fundamental in clinical treatments and pharmacological trials.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:2047-9158
2047-9158
DOI:10.1186/s40035-023-00367-9